Biomarker & Intervention Discovery

Stroke (Secondary Prevention)

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
Gap size
Primary barrier
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

ACE 229F10 242F2 238HMGCR 188ITGB3 15P2RY12 204PCSK9 170PTGS1 281
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SALVIANOLIC ACID B ? unclear Mechanistic
CANDOXATRIL ? unclear Mechanistic
CILAZAPRIL inhibits Mechanistic
TP0556351 inhibits Mechanistic
PRAVASTATIN SODIUM ? unclear Mechanistic
SILDENAFIL ? unclear Mechanistic
GEMFIBROZIL ? unclear Mechanistic
RESCINNAMINE ? unclear Mechanistic
SPIRAPRIL ? unclear Mechanistic
INDOMETHACIN ? unclear Mechanistic
HYDROCHLOROTHIAZIDE ? unclear Mechanistic
ARGIPRESSIN ? unclear Mechanistic
METOPROLOL ? unclear Mechanistic
DELAPRIL inhibits Mechanistic
ACETYLCHOLINE ? unclear Mechanistic
THERAPEUTIC GLUCOCORTICOID ? unclear Mechanistic
IMIDAPRIL inhibits Mechanistic
MALATHION inhibits Mechanistic
MOEXIPRIL ? unclear Mechanistic 56.0 nM (IC50)
VORINOSTAT ? unclear Mechanistic
ILEPATRIL inhibits Mechanistic
RXP470.1 inhibits Mechanistic
CGS-27023A ? unclear Mechanistic
NITROPRUSSIDE ? unclear Mechanistic
ENALAPRILAT ANHYDROUS inhibits Mechanistic 1.2 nM (IC50)
TORSEMIDE ? unclear Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
FOSINOPRIL ? unclear Mechanistic
FUROSEMIDE ? unclear Mechanistic
TEMOCAPRIL HYDROCHLORIDE ? unclear Mechanistic
BENAZEPRIL HYDROCHLORIDE inhibits Mechanistic
CARBARIL inhibits Mechanistic
BUPROPION HYDROCHLORIDE ? unclear Mechanistic
QUINAPRIL ? unclear Mechanistic 8.3 nM (IC50)
COMPOUND 1 [PMID: 24900526] inhibits Mechanistic
COMPOUND 20 [PMID: 22153340] inhibits Mechanistic
BUMETANIDE ? unclear Mechanistic
GALLOPAMIL ? unclear Mechanistic
FLUOXETINE HYDROCHLORIDE ? unclear Mechanistic
AZD6605 inhibits Mechanistic

Showing top 40 of 229 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
FACTOR IX ? unclear Mechanistic
SSR-126517E ? unclear Mechanistic
COAGULATION FACTOR IX ? unclear Mechanistic
COAGULATION FACTOR X HUMAN ? unclear Mechanistic
LETAXABAN ? unclear Mechanistic
IDRAPARINUX ? unclear Mechanistic
COAGULATION FACTOR X, HUMAN ? unclear Mechanistic
NADROPARIN CALCIUM ? unclear Mechanistic
EDOXABAN inhibits Mechanistic
RIVAROXABAN inhibits Mechanistic
THROMBIN ? unclear Mechanistic
LY-517717 ? unclear Mechanistic
SR-123781A ? unclear Mechanistic
ERIBAXABAN inhibits Mechanistic
TRIMETHOPRIM/SULFADOXINE ? unclear Mechanistic
HEPARIN ? unclear Mechanistic
APIXABAN inhibits Mechanistic
MANGIFERIN HEPTASULFATE ? unclear Mechanistic
DX-9065A inhibits Mechanistic
COAGULATION FACTOR VIIA ? unclear Mechanistic
EDOXABAN TOSYLATE inhibits Mechanistic
TANOGITRAN ? unclear Mechanistic
2-O, 3-O DESULFATED HEPARIN ? unclear Mechanistic
BAY 3389934 inhibits Mechanistic
FACTOR VIII ? unclear Mechanistic
SEMULOPARIN ? unclear Mechanistic
IDRABIOTAPARINUX SODIUM inhibits Mechanistic
ANDEXANET ALFA ? unclear Mechanistic
BEMIPARIN inhibits Mechanistic
VITAMIN K3 ? unclear Mechanistic
DAREXABAN inhibits Mechanistic
ANTITHROMBIN III ? unclear Mechanistic
FONDAPARINUX ? unclear Mechanistic
PROTHROMBIN COMPLEX CONCENTRATE ? unclear Mechanistic
DANAPAROID ? unclear Mechanistic
GW-813893 ? unclear Mechanistic
IDRAPARINUX SODIUM inhibits Mechanistic
BETRIXABAN inhibits Mechanistic
NONACOG ALFA ? unclear Mechanistic
EP-217609 ? unclear Mechanistic

Showing top 40 of 242 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
DESIRUDIN inhibits Mechanistic
BIVALIRUDIN inhibits Mechanistic
TAMOXIFEN ? unclear Mechanistic
PEGMUSIRUDIN ? unclear Mechanistic
FLOVAGATRAN ? unclear Mechanistic
ANISINDIONE ? unclear Mechanistic
HEPARIN ? unclear Mechanistic
CATECHIN ? unclear Mechanistic
DABIGATRAN inhibits Mechanistic
DABIGATRAN ETEXILATE MESYLATE inhibits Mechanistic
QUERCETIN ? unclear Mechanistic
ODIPARCIL ? unclear Mechanistic
DPOC-4088 ? unclear Mechanistic
LUSUTROMBOPAG ? unclear Mechanistic
ICHORCUMAB inhibits Mechanistic
PYRIDOXAL PHOSPHATE ANHYDROUS ? unclear Mechanistic
BORTEZOMIB ? unclear Mechanistic 13000.0 nM (Ki)
ANTITHROMBIN ALFA inhibits Mechanistic
SR-123781A ? unclear Mechanistic
ENOXAPARIN SODIUM ? unclear Mechanistic
CYANIDIN ? unclear Mechanistic
CHEMBL:CHEMBL586628 ? unclear Mechanistic
AZD-8165 ? unclear Mechanistic
STAUROSPORINE inhibits Mechanistic
AVATROMBOPAG ? unclear Mechanistic
HIRUDIN ? unclear Mechanistic
CYANIN ? unclear Mechanistic
COMPOUND 2C [PMID: 24900538] inhibits Mechanistic
SILIBININ ? unclear Mechanistic
EP-217609 ? unclear Mechanistic
APRAMIDE A ? unclear Mechanistic
EPICATECHIN ? unclear Mechanistic
ARGATROBAN inhibits Mechanistic
MELAGATRAN ? unclear Mechanistic 4700.0 nM (IC50)
ATECEGATRAN METOXIL inhibits Mechanistic
ASPIRIN TRELAMINE ? unclear Mechanistic
VITAMIN K3 ? unclear Mechanistic
XIMELAGATRAN inhibits Mechanistic
CHEMBL:CHEMBL1083499 ? unclear Mechanistic
DABIGATRAN ETEXILATE ? unclear Mechanistic

Showing top 40 of 238 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
LOVASTATIN inhibits Mechanistic 37.0 nM (IC50)
SIMVASTATIN inhibits Mechanistic 2.6 nM (Ki)
ROSUVASTATIN inhibits Mechanistic 0.9 nM (Ki)
ATORVASTATIN CALCIUM TRIHYDRATE inhibits Mechanistic
FLUVASTATIN inhibits Mechanistic 28.0 nM (IC50)
PRAVASTATIN SODIUM inhibits Mechanistic 1370.0 nM (IC50)
CERIVASTATIN SODIUM inhibits Mechanistic
PITAVASTATIN CALCIUM inhibits Mechanistic
PITAVASTATIN ? unclear Mechanistic
TOCOTRIENOLS ? unclear Mechanistic
CRILVASTATIN ? unclear Mechanistic
ASPIRIN ? unclear Mechanistic
PITAVASTATIN MAGNESIUM inhibits Mechanistic
PITAVASTATIN SODIUM inhibits Mechanistic
CERIVASTATIN ? unclear Mechanistic 10.0 nM (IC50)
LAROPIPRANT ? unclear Mechanistic
TERIFLUNOMIDE ? unclear Mechanistic
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
PRAVASTATIN ? unclear Mechanistic 30.0 nM (IC50)
ROSUVASTATIN CALCIUM ? unclear Mechanistic
ATORVASTATIN CALCIUM ? unclear Mechanistic
ATORVASTATIN ? unclear Mechanistic 6.0 nM (IC50)
FLUVASTATIN SODIUM ? unclear Mechanistic
CHEMBL39102 inhibits Mechanistic 16.0 nM (Ki)
CHEMBL39312 inhibits Mechanistic 3.0 nM (Ki)
CHEMBL175236 inhibits Mechanistic 29.0 nM (IC50)
CHEMBL115307 inhibits Mechanistic 1400.0 nM (IC50)
CHEMBL487720 inhibits Mechanistic 12.0 nM (IC50)
CHEMBL323880 inhibits Mechanistic 2220.0 nM (IC50)
CHEMBL11804 inhibits Mechanistic 3000.0 nM (IC50)
CHEMBL11891 inhibits Mechanistic 1720.0 nM (IC50)
CHEMBL276717 inhibits Mechanistic 1290.0 nM (IC50)
CHEMBL162642 inhibits Mechanistic 0.014 nM (IC50)
CHEMBL159951 inhibits Mechanistic 0.018 nM (IC50)
CHEMBL345375 inhibits Mechanistic 6.0 nM (IC50)
CHEMBL159103 inhibits Mechanistic 5.0 nM (IC50)
CHEMBL2375156 inhibits Mechanistic 0.83 nM (IC50)
CHEMBL163277 inhibits Mechanistic 0.27 nM (IC50)
CHEMBL2375155 inhibits Mechanistic 0.106 nM (IC50)
CHEMBL160102 inhibits Mechanistic 0.05 nM (IC50)

Showing top 40 of 188 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
EPTIFIBATIDE inhibits Mechanistic
ATN-161 inhibits Mechanistic
ABCIXIMAB inhibits Mechanistic
CYPATE ? unclear Mechanistic
INTETUMUMAB inhibits Mechanistic
INTEGRIN RECEPTOR ANTAGONIST GLPG0187 ? unclear Mechanistic
ZALUNFIBAN inhibits Mechanistic
CILENGITIDE inhibits Mechanistic
ANTI-THYMOCYTE GLOBULIN ? unclear Mechanistic
TIROFIBAN HYDROCHLORIDE inhibits Mechanistic
ABITUZUMAB inhibits Mechanistic
TIROFIBAN ? unclear Mechanistic
GANTOFIBAN ? unclear Mechanistic
ETARACIZUMAB inhibits Mechanistic
TADOCIZUMAB inhibits Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
COMPOUND 4 [PMID: 23083103] inhibits Mechanistic
CLOPIDOGREL HYDROCHLORIDE inhibits Mechanistic
MC-1 ? unclear Mechanistic
PRASUGREL ? unclear Mechanistic
2MESADP activates Mechanistic
TREPROSTINIL ? unclear Mechanistic
COMPOUND 58L [PMID: 30843696] inhibits Mechanistic
CLOPIDOGREL ? unclear Mechanistic
TICAGRELOR inhibits Mechanistic 1.995 nM (Ki)
AZD1283 inhibits Mechanistic
AR-C67085 inhibits Mechanistic
R-138727 inhibits Mechanistic
CLOPIDOGREL HYDROBROMIDE inhibits Mechanistic
ADP activates Mechanistic
PSB-22219 inhibits Mechanistic
TICLOPIDINE ? unclear Mechanistic
REGRELOR DISODIUM inhibits Mechanistic
BX 667 inhibits Mechanistic
CYTARABINE ? unclear Mechanistic
PRASUGREL BESYLATE inhibits Mechanistic
[3H]PSB-22219 inhibits Mechanistic
CANGRELOR TETRASODIUM inhibits Mechanistic
CLOPIDOGREL (ACTIVE METABOLITE) inhibits Mechanistic
[3H]AZ12464237 inhibits Mechanistic
INS49266 inhibits Mechanistic
PSB-0739 inhibits Mechanistic
[3H]PSB-0413 inhibits Mechanistic
CLOPIDOGREL BISULFATE inhibits Mechanistic
2MESAMP inhibits Mechanistic
ELINOGREL inhibits Mechanistic
TICLOPIDINE HYDROCHLORIDE inhibits Mechanistic
COMPOUND 20O [PMID: 22984835] inhibits Mechanistic
CANGRELOR inhibits Mechanistic 0.4 nM (IC50)
BX 048 inhibits Mechanistic
ADPΒS activates Mechanistic
PCMBS inhibits Mechanistic
REGRELOR inhibits Mechanistic 16.0 nM (IC50)
COMPOUND 4 [PMID: 22984835] inhibits Mechanistic
PRASUGREL HYDROCHLORIDE inhibits Mechanistic
SELATOGREL inhibits Mechanistic

Showing top 40 of 204 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
ALIROCUMAB inhibits Mechanistic
ONGERICIMAB inhibits Mechanistic
TAFOLECIMAB inhibits Mechanistic
LOMITAPIDE MESYLATE ? unclear Mechanistic
EVOLOCUMAB inhibits Mechanistic
RG-7652 inhibits Mechanistic
BOCOCIZUMAB inhibits Mechanistic
FROVOCIMAB ? unclear Mechanistic
RALPANCIZUMAB inhibits Mechanistic
LERODALCIBEP inhibits Mechanistic
INCLISIRAN ? unclear Mechanistic
INCLISIRAN SODIUM ? unclear Mechanistic
DIPHENYL BORINIC ACID inhibits Mechanistic 30000.0 nM (Ki)
PHENYL BUTYL BORINIC ACID inhibits Mechanistic 1000.0 nM (Ki)
CHEMBL4107804 inhibits Mechanistic 3200.0 nM (IC50)
CHEMBL4107907 inhibits Mechanistic 1700.0 nM (IC50)
CHEMBL4114159 inhibits Mechanistic 800.0 nM (IC50)
CHEMBL4108338 inhibits Mechanistic 1500.0 nM (IC50)
CHEMBL4107714 inhibits Mechanistic 1500.0 nM (IC50)
CHEMBL4110311 inhibits Mechanistic 9500.0 nM (IC50)
CHEMBL4107559 inhibits Mechanistic 1800.0 nM (IC50)
CHEMBL4114106 inhibits Mechanistic 1500.0 nM (IC50)
CHEMBL4109097 inhibits Mechanistic 11700.0 nM (IC50)
CHEMBL4108330 inhibits Mechanistic 2300.0 nM (IC50)
CHEMBL4109114 inhibits Mechanistic 4500.0 nM (IC50)
CHEMBL3961039 inhibits Mechanistic 7300.0 nM (IC50)
CHEMBL4112247 inhibits Mechanistic 10700.0 nM (IC50)
CHEMBL4109308 inhibits Mechanistic 800.0 nM (IC50)
CHEMBL4109014 inhibits Mechanistic 11820.0 nM (IC50)
CHEMBL4108567 inhibits Mechanistic 3800.0 nM (IC50)
CHEMBL4111131 inhibits Mechanistic 18000.0 nM (IC50)
CHEMBL4115372 inhibits Mechanistic 1700.0 nM (IC50)
CHEMBL4106481 inhibits Mechanistic 3050.0 nM (IC50)
CHEMBL4108186 inhibits Mechanistic 5610.0 nM (IC50)
CHEMBL4115360 inhibits Mechanistic 5800.0 nM (IC50)
CHEMBL4114503 inhibits Mechanistic 25300.0 nM (IC50)
CHEMBL4108540 inhibits Mechanistic 2970.0 nM (IC50)
CHEMBL4109409 inhibits Mechanistic 5750.0 nM (IC50)
CHEMBL4109932 inhibits Mechanistic 14300.0 nM (IC50)
CHEMBL4106569 inhibits Mechanistic 16800.0 nM (IC50)

Showing top 40 of 170 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CURCUMIN PYRAZOLE ? unclear Mechanistic
BROMFENAC inhibits Mechanistic
FLURBIPROFEN inhibits Mechanistic
DIFLUNISAL inhibits Mechanistic
URSOLIC ACID ? unclear Mechanistic
NEPAFENAC inhibits Mechanistic
SALICYLIC ACID ? unclear Mechanistic
IBUPROFEN, SODIUM SALT inhibits Mechanistic
INDOMETHACIN SODIUM inhibits Mechanistic
NAPROXEN ETEMESIL inhibits Mechanistic
PIROXICAM-BETA-CYCLODEXTRIN inhibits Mechanistic
SUPROFEN inhibits Mechanistic
MECLOFENAMATE inhibits Mechanistic
NITRIC OXIDE-RELEASING ACETYLSALICYLIC ACID DERIVATIVE ? unclear Mechanistic
MEFENAMIC ACID inhibits Mechanistic
FENOPROFEN inhibits Mechanistic
PHENYLBUTAZONE inhibits Mechanistic
APAZONE inhibits Mechanistic
OXAPROZIN POTASSIUM inhibits Mechanistic
FENOPROFEN CALCIUM inhibits Mechanistic
ICOSAPENT ETHYL ? unclear Mechanistic
(S)-ARN2508 inhibits Mechanistic
SWE101 inhibits Mechanistic
MELOXICAM inhibits Mechanistic 2200.0 nM (IC50)
ISOXICAM inhibits Mechanistic
DICLOFENAC POTASSIUM inhibits Mechanistic
TEPOXALIN inhibits Mechanistic
IBUPROFEN LYSINE inhibits Mechanistic
ACEMETACIN inhibits Mechanistic
DERSALAZINE ? unclear Mechanistic
FK-881 inhibits Mechanistic
(R)-ARN2508 inhibits Mechanistic
OXAPROZIN inhibits Mechanistic
BENZYDAMINE HYDROCHLORIDE inhibits Mechanistic
ASPIRIN inhibits Mechanistic
OLSALAZINE SODIUM inhibits Mechanistic
KETOROLAC TROMETHAMINE inhibits Mechanistic
SALSALATE ? unclear Mechanistic
ANTIVIRAL AGENT ? unclear Mechanistic
LORNOXICAM inhibits Mechanistic

Showing top 40 of 281 agents ranked by evidence tier.


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.

NCT03419325 Phase: EARLY_PHASE1 Started: 2020-09-01

Clopidogrel is a prescription medicine used to minimize blood clot formation in patients with cardiovascular disease, particularly those undergoing heart catheterization and stroke. A substantial amount of medical evidence has proven that patients with stroke or heart diseases can benefit from this ...

NCT07414732 Phase: NA Started: 2026-03-31

The goal of this study is to test if Savvy, a multimodal intervention (consisting of psychological exercises, a weekly pill organizer, and a text message reminder system) can improve medication adherence in stroke survivors. The main questions it aims to answer are: * Can the Savvy tool improve me...

NCT06292117 Phase: N/A Started: 2024-04-16

The goal of this observational study is to use a genetic test to help doctors prescribe the most effective medications after a patient has a stroke. One type of stroke is caused by a blood clot in brain vessels. After a patient has this kind of stroke, they are often given a combination of two blood...

NCT06832579 Phase: NA Started: 2025-05-15

Unrecognized atrial fibrillation (AF) is a common cause of ischemic stroke. Implantable event monitors (ICM) are the gold standard for continuous heart rhythm monitoring but they have been implemented in very few patients after stroke due to high invasiveness and high costs. In this trial, patients...

NCT06820411 Phase: NA Started: 2025-01-20

Purpose The Y-SCOPE study aims to improve the health and recovery of young adults aged 18 to 65 who have experienced an ischemic stroke or a high-risk transient ischemic attack (TIA). By focusing on personalized care and lifestyle changes, the study seeks to reduce the chances of another stroke and ...

NCT06714097 Phase: NA Started: 2026-04

The goal of this clinical trial is to obtain initial feedback on the implementation of the STRATIF-AI platform and digital twin in the secondary prevention phase in patients with stroke, Moyamoya disease and Cerebral amyloid angiopathy, including adults of both sexes. The main questions it aims to ...

NCT05646589 Phase: NA Started: 2022-11-21

The goal of this clinical trial is to test a person-centred care transition support in people with stroke/TIA. The main questions it aims to answer are: * Does a multi-component care transition intervention have an effect on perceived quality of care transitions, health literacy, collected medicati...

NCT07407790 Phase: NA Started: 2026-01-10

This study evaluates whether a procedure using a new wireless heart sensor patch is equal to or better than the standard hospital procedures and equipment at detecting an irregular heartbeat called Atrial Fibrillation (AF) after an ischemic stroke. Atrial fibrillation is a major cause of stroke, but...

NCT06783049 Phase: NA Started: 2025-03-03

The purpose of this study is to develop a digital health-based intelligent management system for the secondary prevention of ischemic stroke and to evaluate its effectiveness through a multicenter randomized controlled trial, assessing its health economic value. Participants will receive usual care...

NCT06450561 Phase: N/A Started: 2024-03-01

The present observational study aims to determine the degree of adherence to the recommendations of clinical guidelines regarding the prevention of cardiovascular complications in patients hospitalized due to a cardiovascular event.

NCT02132364 Phase: NA Started: 2014-01-30

The main objective of the study is to compare the benefit of optimised follow-up by nursing personnel from the vascular neurology department, including therapeutic follow-up and an educational program directed to the patient and a caregiving member of his social circle, with that of a typical follow...

NCT03153020 Phase: N/A Started: 2017-09-11

The effectiveness of emergency management of acute ischemic stroke has improved considerably in recent years with thrombolysis and more recently thrombectomy. This improvement is accompanied by an increase in the number of stroke survivors. One of the major issues for these ever-increasing survivors...

NCT07194811 Phase: N/A Started: 2016-05

The goal of this observational study is to investigate sex - differences in detection rate of atrial fibrillation after cryptogenic stroke (embolic stroke of unknown cause) - using an implantable cardiac rhythm monitor - and the treatment effects of oral anticoagulation on recurrent stroke, ischemic...

NCT03859063 Phase: NA Started: 2019-04-11

Despite the improved treatment of acute stroke over the past decades, those suffering from stroke still are at an increased risk of functional and cognitive decline in the long term. The most common consequences of stroke are functional impairments, cognitive impairments, depression and fatigue. The...

NCT07119047 Phase: NA Started: 2025-05-01

Introduction: Low- and middle-income countries, such as Brazil, are most impacted by the high burden of recurrent stroke. These countries also lack structured interventions to promote the adoption of healthy lifestyle behaviors in the context of stroke secondary prevention. In contrast, high-income ...


Agents Found By Disease-Level Search

Searched directly from “Stroke (Secondary Prevention)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.